Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TCRX
#3154
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-3.64%
Monatliche Änderung
-4.50%
6 month change
-43.32%
Jahresänderung
-48.29%
Vorheriger Schlusskurs
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Volumen
6
Märkte
Aktien
Gesundheitswesen
TCRX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
Nachrichten
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Ações da Tscan Therapeutics mantêm classificação neutra da BTIG após evento ASH
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Morgan Stanley rebaixa ações da Tscan Therapeutics devido a atrasos nos ensaios
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Lucro da Tscan Therapeutics superou projeções por $0,06; receita supera estimativas